Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems.
Kymera Therapeutics is a clinical-stage biotech company pioneering targeted protein degradation (TPD) to improve treatment options for diseases. They are focused on developing a pipeline of orally small molecule degraders with a strong science, robust collaborations, and a commitment to diverse and inclusive teams. The company has been recognized as one of Boston's top workplaces in recent years.
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems.